SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ trends as the market grapples with the fallout from the Supreme Court's tariff ruling and the subsequent 15% global tariffs, fueling community debate on economic uncertainty and the tech index's consistent resilience ahead of Nvidia's pivotal earnings.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting highly positive Phase 2 S-OLARIS trial results for sonelokimab in axial spondyloarthritis, showcasing strong efficacy and potential disease-modifying effects. This, combined with a robust financial position and an eagerly awaited Investor Day, is fueling community discussion around significant undervaluation, a potential short squeeze, and best-in-class potential for its nanobody platform.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending amid renewed uncertainty surrounding global trade policy, driven by recent tariff decisions that have sparked market volatility. The community is sharply divided, with bears anticipating a major downturn following weekend declines, while bulls expect a typical 'V-shape' recovery, particularly ahead of key tech earnings this week.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending as the community eagerly discusses the recent FDA approval of Bysanti for bipolar I disorder and schizophrenia, with many anticipating a significant valuation re-rating and potential for a short squeeze, especially given the drug's patent protection until 2044 and the broader 'mega blockbuster' potential of its pipeline.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is currently trending as rival Hims & Hers has halted its compounded weight-loss pill following legal action from NVO and increased FDA scrutiny on such alternatives, reinforcing NVO's market leadership. The community is actively discussing the implications of this development alongside Novo's promising oral Wegovy launch momentum and ongoing share buyback program.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is trending as investors await its earnings report and upcoming presentations of positive Navenibart trial data, a recently acquired long-acting HAE prophylactic. This is fueling community debate between optimism driven by institutional interest and persistent concerns over significant short positions.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as Novo Nordisk's recent CagriSema trial results fuel intense community speculation that VKTX's 'best-in-class' VK2735 obesity drug is now an even more attractive buyout or partnership target for major pharmaceutical companies like AbbVie, given its strong efficacy and tolerability in the rapidly expanding weight loss market.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending due to its succession of record-breaking battery swaps, including hitting 1 million weekly swaps during the Chinese New Year holiday, which bulls highlight as proof of its BaaS ecosystem's strength and a precursor to anticipated profitability. However, the community remains divided, with skeptics dismissing holiday-inflated numbers and alleging continued stock manipulation, while broader discussions also focus on the potential impact of recent tariff rulings.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending due to a dual financing announcement, including a non-dilutive royalty deal for its prostate cancer candidate and a concurrent public offering, which has sparked intense community debate over dilution and management's long-term commercialization strategy. Bulls view the capital raise as crucial validation and runway for its promising oncology pipeline, while bears express strong concerns about shareholder value and the impact on a potential "go it alone" approach.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind Corp is trending due to upcoming catalysts, including the FDA's PDUFA date in May 2026 for pediatric Afrezza and the recent launch of Afrezza in India, alongside its impending Q4 earnings report. The community is sharply divided between those anticipating significant growth from these developments and skeptics highlighting Afrezza's historical performance and expressing concerns over management.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$VERA Novel B cell modulator, potential paradigm shift to treat other autoimmune disorders beyond nephrology. In their latest call mentioned 11 different indications that they believe can show improvement.

flamingojack

Alan Purdie

StockTwits for iOS

Vera Therapeutics Inc - Ordinary Shares - Class A

 Novel B cell modulator, potential paradigm shift to treat other autoimmune disorders beyond nephrology. In their latest call mentioned 11 different indications that they believe can show improvement.

Immutep LTD ADR

Iovance Biotherapeutics Inc

Revolution Medicines Inc

Immix Biopharma Inc

Immuneering Corp

BridgeBio Oncology Therapeutics Inc.

Kari

Sangamo Therapeutics Inc

Lockheed Martin Corp.

Sarepta Therapeutics Inc

MP Materials Corporation

Nuburu Inc - Ordinary Shares - Class A

Rocket Lab USA Inc

Fintechfrank

@Fintechfrank That’s a hard call to make.  This is a buyout candidate in my mind.  Given enough time it could be worth that.

 That’s a hard call to make.  This is a buyout candidate in my mind.  Given enough time it could be worth that.

@Fintechfrank The word “buyout” rarely leaves my lips. I don’t find many that fit the criteria.

 The word “buyout” rarely leaves my lips. I don’t find many that fit the criteria.